Travere Therapeutics, Inc. (TVTX) is a San Diego-based biopharmaceutical company dedicated to developing innovative therapies for rare metabolic and genetic disorders. With a strong pipeline designed to tackle significant unmet medical needs, the company emphasizes rapid development and commercialization of its treatments. Travere is committed to enhancing patient outcomes and transforming healthcare solutions for underserved populations, leveraging advanced scientific research and strategic collaborations to drive growth and value. Show more

Location: 3611 VALLEY CENTRE DRIVE, SAN DIEGO, CA, UNITED STATES, 92130, San Diego, CA, 92130, USA | Website: https://www.travere.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.782B

52 Wk Range

$12.91 - $42.13

Previous Close

$31.09

Open

$31.09

Volume

1,577,799

Day Range

$31.04 - $33.14

Enterprise Value

2.937B

Cash

110.9M

Avg Qtr Burn

N/A

Insider Ownership

0.74%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FILSPARI (Sparsentan) Details IgA nephropathy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
THIOLA® EC (tiopronin) Details Kidney disease, Cystinosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FILSPARI (Sparsentan) Details Focal segmental glomerulosclerosis (FSGS)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CDCA (Chenodal/ chenodeoxycholic acid) Details Cerebrotendinous xanthomatosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pegtibatinase (TVT-058) Details Homocystinuria	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sparsentan Details Kidney disease, Glomerular diseases	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.